Back to Journals » Neuropsychiatric Disease and Treatment » Volume 5

Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study

Authors Torsdottir G, Gudmundsson G, Kristinsson J, Snaedal J, Jóhannesson T

Published 6 March 2009 Volume 2009:5 Pages 55—59

DOI https://doi.org/10.2147/NDT.S4360

Review by Single-blind

Peer reviewer comments 6


Gudlaug Tórsdóttir1,2, Grétar Gudmundsson3, Jakob Kristinsson1, Jón Snaedal2, Torkell Jóhannesson1

1Institute of Pharmacy, Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Iceland, Reykjavík, Iceland; 2Department of Geriatrics; 3Department of Neurology, Landspítali – University Hospital, Reykjavík, Iceland

Abstract: At the time of this study, there were five known patients with Wilson disease (WD) in Iceland. The mutation, a 7-bp deletion in exon 7 on chromosome 13 for WD, is only known in Iceland. In twenty healthy Icelandic heterozygotes for WD and their age- and gender-matched controls, copper concentration in plasma, ceruloplasmin (CP) concentration, CP oxidative activity and CP-specific oxidative activity in serum and superoxide dismutase (SOD1) activity in erythrocytes were determined. The same determinations were done on the five WD patients. There was no significant difference in these parameters between the heterozygotes and the controls, although an inclination toward lower CP determinations and higher SOD1 activity in the heterozygotes was noted. As expected the WD patients were low on the copper and CP parameters, but their SOD1 activity was within the upper normal range. In conclusion, the CP parameters and SOD1 activity are within the normal range in Icelandic heterozygotes for WD, although with a trend toward mild dyshomeostasis. This may indicate subclinical copper retention in the heterozygotes, but a bigger study group is needed to confirm this.

Keywords: ceruloplasmin, SOD1, heterozygotes, Wilson disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]